Valuation: Bioventix PLC

Market Cap 78.37M 105M 91.5M 85.68M 148M 10.04B 150M 1B 393M 5.02B 396M 387M 16.7B P/E 2026 *
11.2x
P/E 2027 * -
Enterprise Value 73.48M 98.85M 85.78M 80.33M 139M 9.42B 141M 940M 369M 4.7B 371M 363M 15.66B EV / Sales 2026 *
5.88x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
10%
Yield 2027 * -
1 week-0.66%
Current month-0.66%
1 month-5.66%
3 months-11.76%
6 months-11.76%
Current year-21.26%
1 week 1,470
Extreme 1470
1,550
1 month 1,470
Extreme 1470
1,650
Current year 1,300
Extreme 1300
1,950
1 year 1,300
Extreme 1300
2,550
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 23/12/2003
Director of Finance/CFO 67 01/07/2020
Director TitleAgeSince
Director/Board Member 67 25/11/2010
Chairman 66 01/11/2004
Director/Board Member 67 01/07/2020
Date Insider Type Main position Quantity % Market Cap.
20/04/26 Free

Chief Financial Officer

9,967 0.1908%
26/11/25 Buy

Chief Financial Officer

150 0.0029%
04/11/25 Buy

Chief Executive Officer

875 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.66%-40.59%-60.53% 105M
+0.23%-0.63%+3.89%+14.93% 48.7B
+0.26%+2.93%+439.43%+533.80% 42.05B
-1.53%-2.25%+30.95%+7.15% 38.26B
+0.69%+2.40%+10.48%+63.05% 37.5B
+2.47%+2.63%+14.71%+48.37% 31.44B
-0.47%+1.16%+35.93%+126.09% 16.33B
+2.31%-0.49% - - 16.47B
+0.29%+2.46%+6.30%+18.94% 13.98B
-1.43%-2.63%+3.70%-36.38% 12.43B
Average +0.25%+0.62%+56.09%+79.49% 25.73B
Weighted average by Cap. +0.30%+0.94%+88.97%+121.26%

Financials

2026 *2027 *
Net sales 12.5M 16.82M 14.59M 13.66M 23.6M 1.6B 23.91M 160M 62.74M 800M 63.14M 61.77M 2.66B -
Net income 7.11M 9.57M 8.3M 7.77M 13.43M 911M 13.6M 90.96M 35.7M 455M 35.92M 35.14M 1.52B -
Net Debt -4.89M -6.58M -5.71M -5.35M -9.24M -627M -9.36M -62.59M -24.56M -313M -24.72M -24.18M -1.04B -
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
06/08/26 GBX 1,500.00 0.00% 2,922
05/08/26 GBX 1,500.00 -0.66% 13,162
04/08/26 GBX 1,510.00 0.00% 31,295
03/08/26 GBX 1,510.00 0.00% 11,151
31/07/26 GBX 1,510.00 0.00% 12,433
Trader
Investor
Global
-
Quality
ESG MSCI
CCC

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BVXP Stock